Patents by Inventor Michael P. Arend

Michael P. Arend has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 8278325
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: October 2, 2012
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric Turtle, Xiaohui Du
  • Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
    Patent number: 8269008
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF) by inhibiting the activity of at least one HIF hydroxylase enzyme.
    Type: Grant
    Filed: December 2, 2008
    Date of Patent: September 18, 2012
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Heng Cheng, Lee A. Flippin, Danny Ng, Eric D. Turtle, Min Wu
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20120029011
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: July 19, 2011
    Publication date: February 2, 2012
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 8017625
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: September 13, 2011
    Assignee: Fibrogen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Web-Bin Ho, Eric Turtle, Xiaohui Du
  • Cyanoisoquinoline Compounds and Methods of Use Thereof
    Publication number: 20110212959
    Abstract: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions.
    Type: Application
    Filed: March 7, 2011
    Publication date: September 1, 2011
    Inventors: Michael P. Arend, Lee A. Flippin, Min Wu, Eric D. Turtle, Wen-Bin Ho, Shaojiang Deng
  • Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase
    Publication number: 20110166178
    Abstract: The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.
    Type: Application
    Filed: February 17, 2011
    Publication date: July 7, 2011
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Al Y. Lin, Thoams B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Stabilization of hypoxia inducible factor (HIF) alpha
    Publication number: 20110166145
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Application
    Filed: December 2, 2010
    Publication date: July 7, 2011
    Applicant: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 7863292
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: January 19, 2007
    Date of Patent: January 4, 2011
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric Turtle, Xiaohui Du
  • ISOTHIAZOLE-PYRIDINE DERIVATES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY
    Publication number: 20100330199
    Abstract: The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).
    Type: Application
    Filed: January 12, 2009
    Publication date: December 30, 2010
    Inventors: Xiaoti Zhou, Michael P. Arend, Min Wu, Lee A. Flippin
  • ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS
    Publication number: 20100303928
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF) by inhibiting the activity of at least one HIF hydroxylase enzyme.
    Type: Application
    Filed: December 2, 2008
    Publication date: December 2, 2010
    Applicant: FibroGen, Inc.
    Inventors: Michael P. Arend, Heng Cheng, Lee A. Flippin, Danny Ng, Eric D. Turtle, Min Wu
  • Pyrrolo- and Thiazolo-pyridine compounds, and methods of use thereof
    Patent number: 7696223
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: April 13, 2010
    Assignee: FibroGen, Inc.
    Inventors: Shaojiang Deng, Min Wu, Eric D. Turtle, Wen-Bin Ho, Michael P. Arend, Heng Cheng, Lee A. Flippin
  • Nitrogen-containing heteroaryl compounds and methods of user thereof
    Patent number: 7629357
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: December 8, 2009
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Web-Bin Ho, Eric Turtle, Xiaohui Du
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20080293763
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: January 16, 2008
    Publication date: November 27, 2008
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Web-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 7323475
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: January 29, 2008
    Assignee: Fibrogen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric Turtle, Xiaohui Du
  • Novel nitrogen-containing heteroaryl compounds and methods of use thereof
    Publication number: 20040254215
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: June 4, 2004
    Publication date: December 16, 2004
    Applicant: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Stabilization of hypoxia inducible factor (HIF) alpha
    Publication number: 20030176317
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Application
    Filed: December 6, 2002
    Publication date: September 18, 2003
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Methods of increasing endogenous erythropoietin (EPO)
    Publication number: 20030153503
    Abstract: The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.
    Type: Application
    Filed: December 6, 2002
    Publication date: August 14, 2003
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Michael P. Arend, Lee A. Flippin, Alex Melekhov